Agios’ Sarah Gheuens exercises options, sells shares

The Chief Medical Officer's sales were tied to a Rule 10b5-1 trading plan, while the reported options carried a $25.01 exercise price.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Agios Pharmaceuticals, Inc. Chief Medical Officer Sarah Gheuens exercised options to acquire 1,489 shares on October 21, 2026, and 500 shares on October 22, 2026, at an exercise price of $25.01 per share. She sold the same share amounts on those dates at $37.53 and $37.52 per share, respectively. Both sales were made under a Rule 10b5-1 trading plan; the October 21 sale price was a weighted average of sales ranging from $37.52 to $37.55.

Insider Trade Summary 10b5-1

Exercise and Sale: 1,989 shares ($25K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Gheuens Sarah

Role Chief Medical Officer

Sold 1,989 shs ($75K)

Approx. gross sale proceeds $75K

Approx. exercise cost $50K

Approx. pre-tax spread $25K

Type	Security	Shares	Price	Value
Exercise	Stock options (right to buy) ^F3	500	$0.00	$0.00
Exercise	Common stock	500	$25.01	$13K
Sale	Common stock ^F1	500	$37.52	$19K
Exercise	Stock options (right to buy) ^F3	1,489	$0.00	$0.00
Exercise	Common stock	1,489	$25.01	$37K
Sale	Common stock ^{F1, F2}	1,489	$37.53	$56K

Holdings After Transaction: Stock options (right to buy) — 24,141 contracts (Direct); Common stock — 54,645 shares (Direct)

Footnotes (3)

F1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $37.52 to $37.55. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3. This option was granted on March 1, 2023. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Key Figures

Options exercised: 1,489 shares Options exercised: 500 shares Exercise price: $25.01 per share +4 more

7 metrics

Options exercised 1,489 shares October 21, 2026

Options exercised 500 shares October 22, 2026

Exercise price $25.01 per share Reported option exercises

Shares sold 1,489 shares October 21, 2026

Weighted average sale price $37.53 per share October 21, 2026; sales ranged from $37.52 to $37.55 per share

Shares sold 500 shares October 22, 2026

Sale price $37.52 per share October 22, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average, exercise price, vesting

4 terms

Rule 10b5-1 trading plan regulatory

"sale was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average financial

"The price reported is the weighted average of the shares sold"

A weighted average is a way of calculating an overall number when some items matter more than others by giving each item a different level of importance, or weight. Investors use weighted averages to combine figures like prices, returns or earnings so the result reflects the size or significance of each part — like grading a class where a final exam counts more than a quiz, producing a score that better represents true performance.

exercise price financial

"conversion_or_exercise_price: 25.0100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"remaining 75% vesting in 36 equal monthly installments thereafter"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AGIO shares did Sarah Gheuens sell?

Sarah Gheuens sold 1,489 AGIO shares on October 21, 2026, at a weighted average $37.53 per share, and 500 shares on October 22, 2026, at $37.52 per share. Both sales were under a Rule 10b5-1 trading plan.

What were the vesting terms for Sarah Gheuens's AGIO options?

The options were granted March 1, 2023; 25% of the underlying shares vest on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/23/2026 - 04:06 PM EDT Accepted by SEC EDGAR 10/23/2026 - 04:05 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gheuens Sarah

(Last)

(First)

(Middle)

88 SIDNEY STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02139

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AGIOS PHARMACEUTICALS, INC. [ AGIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock	10/21/2026		M		1,489	A	$25.01	56,134	D
Common stock	10/21/2026		S⁽¹⁾		1,489	D	$37.53⁽²⁾	54,645	D
Common stock	10/22/2026		M		500	A	$25.01	55,145	D
Common stock	10/22/2026		S⁽¹⁾		500	D	$37.52	54,645	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock options (right to buy)	$25.01	10/21/2026		M			1,489	⁽³⁾	03/01/2033	Common stock	1,489	$0	24,641	D
Stock options (right to buy)	$25.01	10/22/2026		M			500	⁽³⁾	03/01/2033	Common stock	500	$0	24,141	D

Explanation of Responses:

1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

2. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $37.52 to $37.55. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

3. This option was granted on March 1, 2023. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Remarks:

	/s/ William Cook, as attorney-in-fact for Sarah Gheuens	10/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR